Abstract: A clinically-relevant, drug-resistant mutant of HIV-1 protease (PR), termed Flap+(I54V) and containing L10I, G48V, I54V and V82A mutations, is known to produce significant changes in the entropy and enthalpy balance of drug-PR interactions, compared to wild-type PR.
Abstract: To understand the molecular basis of V54A evolution, we compared nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectroscopy, isothermal titration calorimetry, and enzymatic assay data from four PR proteins: PR (pWT), Flap+(I54V) , Flap+( PMID: 32267869
2020
PloS one
Result: Minor PI mutations detected among the isolates include; L10I/V [7/28 (25.0%)], K20I [28/28 (100%)], L33F [1/28 (3.6%)] and N88D [1/28 (3.6%)].
Table: L10I
Discussion: <
Discussion: In line with this, the only isolate with V82L mutation in this study, NG_IM.12_07, also harbours N88D mutation in addition to L10I and K20I mutations.
Discussion: Our study also revealed very high frequencies of minor mutations in the protease gene of the isolates with the predominant mutations found at positions L10I/V and K20I.
Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.
Introduction: Two mutations in PRS5B have a major association with drug-resistance (M46L and I84V), while nine are classified as minor drug resistance mutations (L10I, V11I, M36I, I54V, I62V, I63P,
Result: L10I and L63P did not show structural changes in PRS5B but have been shown to help maintain thermal stability when combined with I84V.
Result: Mutation L10I in Loop 1 of PRS5B was excluded from the designated clusters due to absence of significant structural changes as also seen for the same mutation in the PRS17/DRV structure.
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Introduction: Previous research in Ghana has shown low prevalence (5%) of drug resistance, with some studies reporting no transmitted drug resistance mutations, while others observed only minor mutations L10I, L10 V, V11I, and E35G in 4 patients and V179E in another.
HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.
Result: Three minor HIV protease inhibitor-related mutations (L10I, L10V, and G73S) were also detected in four patients, although these mutations are not included in the WHO SDRMs list (Table 4).
Table: L10I
Multidrug-resistant HIV viral rebound during early syphilis: a case report.
Conclusion: A genotype resistance test (GRT) in June 2002 (Trugene HIV-1 Genotyping Assay, Siemens Healthcare Diagnostics GmbH, Eschborn, Germany) showed extensive resistance in the RT region (M41L, E44D, D67N, V118L, M184V, L210W, and T215Y) and the PR region (L10I, M46L, L63P, V82T, and L90M), and a tropism test in 2013 (envelope glycoprotein (gp)120 V3 loop sequencing) revealed a C-C chemokine receptor type 5 (CCR5) tropic virus with a false positive rate of 91.3% (geno2pheno c
Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study.
Result: The most common mutations in NNRTIs were K103N/KN (64.69%), V179D/E (23.47%) and Y181C/YC/I (14.00%), they were M184V/MV/I (36.29%), T215F/FS/TNSY (7.50%) and K219Q (5.92%) in NRTIs, and they were Q58E/QE (4.93%), L10F/LFI (0.39%) and M46L (0.39%) in PIs.
Figure: Note: PIs mutations: M46I, I54V, V82A, K20T,
Detection of human immunodeficiency virus type 1 transmitted drug resistance among treatment-naive individuals residing in Jakarta, Indonesia.
Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naive Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan.
Result: The most common RAMs to NRTIs were M184V and K65R (1.3%), while those for NNRTIs were V179D (4.5%), V106I (2.7%), and K103N (1.3%), and those for PIs were L10I (13.4%), A71T (5.8%), and L10V (4.0%).
Figure: The figure shows that the most common drug resistance-associated mutations were M184V (1.3%) and K65R (1.3%) for NRTIs, V179D (4.5%), V106I (2.7%) and K103N (1.3%) for
ViMRT
HIV mutation literature information.
PMID: 
2022
Antimicrobial agents and chemotherapy
